Company
Moderna ($MRNA)
- Headquarters:
- Cambridge, MA
- Funding:
- $590M · Series C+ · Apr 2025
Description
Develops mRNA medicines using a platform for designing, researching, and testing mRNA, with a focus on addressing infectious and serious diseases.
Related
BioNTechBioNTech develops investigational therapies for cancer and infectious diseases, including mRNA cancer immunotherapies, immunomodulators,…
Vertex Pharmaceuticals ($VRTX)Discovers, develops, and produces medicines for people with serious diseases, while offering treatment support and information about…
Beam Therapeutics ($BEAM)Develops investigational base-editing genetic medicines and delivery technologies, including electroporation, nonviral, and viral methods,…
Arbor BiotechnologiesDevelops gene editing treatments and genetic medicines using programmable DNA editors for people with genetic diseases, with a focus on CNS…
Editas Medicine ($EDIT)Develops CRISPR-based gene editing medicines, including in vivo approaches, for people with serious diseases where modifying genes may…
Intellia Therapeutics ($NTLA)Develops gene-editing medicines for serious diseases. Its clinical programmes use CRISPR delivered inside the body to treat inherited…
Merck Cambridge Discovery ($MRK)Develops medicines and vaccines through research, clinical trials, and publications, focusing on diseases including cancer, infectious,…
Relay Therapeutics ($RLAY)Develops small molecule medicines using computational and experimental protein-motion analysis, targeting previously hard-to-drug precision…
Cartesian Therapeutics ($RNAC)Develops clinical-stage mRNA cell therapies designed to treat autoimmune diseases, aiming to expand access to cell therapy for patients…
Krystal Biotech ($KRYS)Develops and delivers redosable genetic medicines, including VYJUVEK for dystrophic epidermolysis bullosa, using engineered HSV-1 vectors…
Vertex Pharmaceuticals (San Diego)Discovers, develops, and produces medicines for serious diseases, while providing medical information, patient support, and clinical trial…
Ionis Pharmaceuticals ($IONS)Develops RNA- and DNA-targeted medicines for people with serious diseases, with marketed therapies including TEGSEDI and WAYLIVRA for…
Timeline
series-c-plus · $590M · led by BARDAmodernatx.com ↗
seed · Seed · led by Flagship Pioneeringmodernatx.com ↗